Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
NCT02937168 · Teva Branded Pharmaceutical Products R&D, Inc. · PHASE4 · terminated · last registry update 2021-11-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated early due to challenges in recruitment. The decision to terminate the study was not related to any safety issues or concerns.” | – | Registry record, Teva Branded Pharmaceutical Products R&D, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL5 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-06-21Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Mepolizumab + Placebo (NCT03292588)
- 2022-04-19Phase 3 first posted: GlaxoSmithKline, Depemokimab (NCT05334368)
- 2022-03-16Phase 3 first posted: GlaxoSmithKline, Depemokimab (GSK3511294) + Placebo (NCT05281523)
- 2022-03-10Phase 3 first posted: GlaxoSmithKline, Depemokimab (GSK3511294) + Placebo (NCT05274750)
- 2022-03-03Phase 3 first posted: GlaxoSmithKline, Depemokimab + Mepolizumab (NCT05263934)
- 2022-02-17Phase 3 first posted: GlaxoSmithKline, GSK3511294 (Depemokimab) (NCT05243680)
- 2021-11-30Phase 3 first posted: Sheffield Teaching Hospitals NHS Foundation Trust, Mepolizumab 100 MG (NCT05138250)
- 2021-09-01Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Mepolizumab + cyclophosphamide/azathioprine (NCT05030155)
- 2021-07-16Phase 3 first posted: GlaxoSmithKline, Mepolizumab (NCT04965636)
- 2021-01-22Phase 3 first posted: GlaxoSmithKline, GSK3511294 (Depemokimab) + Mepolizumab (NCT04718389)
- 2021-01-22Phase 3 first posted: GlaxoSmithKline, GSK3511294 (Depemokimab) + Placebo (NCT04719832)
- 2021-01-22Phase 3 first posted: GlaxoSmithKline, GSK3511294 + Placebo (NCT04718103)
- 2020-12-17Results posted on the registry: GlaxoSmithKline, Mepolizumab + Placebo (NCT03085797)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision